Discontinuing disease-modifying therapy in progressive multiple sclerosis: Can we stop what we have started?

Multiple Sclerosis

Volumn 15, Issue 12, 2009, Pages 1528-1531

  Lonergan, Roisín ^a   Kinsella, Katie ^a   Duggan, Marguerite ^a   Jordan, Sinead ^a   Hutchinson, Michael ^a   Tubridy, Niall ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cost; Disease modifying therapies; Progressive multiple sclerosis; Stopping criteria

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; COST CONTROL; DISEASE COURSE; DRUG USE; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT CARE; PHYSICIAN ATTITUDE; RURAL AREA;

ADULT; COST SAVINGS; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; GUIDELINE ADHERENCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRELAND; MEDICAL FUTILITY; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RURAL HEALTH SERVICES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; URBAN HEALTH SERVICES;

EID: 72749090844     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509351730     Document Type: Article

References (14)

1. Waubant E., Vukusic S., Gignoux L., et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003 ; 61: 184-189.
2. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 ; 46: 907-911.
3. Kappos L., Weinshenker B., Pozzilli C., et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004 ; 63: 1779-1787.
4. Cohen JA, Antel JP Does interferon beta help in secondary progressive MS? Neurology 2004 ; 63: 1768-1769.
5. Rojas JI, Romano M., Ciapponi A., Patrucco L., Cristiano E. Interferon beta for primary progressive multiple sclerosis. Cochrane Database of Systematic Reviews 2009 ; 1: CD006643. DOI: 10.1002/14651858.CD006643.pub2.
6. Trojano M., Pellegrini F., Fuiani A., et al. New natural history of interferon-β- treated relapsing multiple sclerosis. Ann Neurol 2007 ; 61: 300-306.
7. Association of British Neurologists. ABN guidelines for treatment of multiple sclerosis with β-interferon and glatiramer acetate 2007. London: Association of British Neurologists, 2007.
8. Goodin DS, Frohman EM, Garmany JR, et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 ; 58: 169-178.
9. Polman CH, OConnor PW, Havrdova E., et al. for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
10. Polman CH, Reingold SC, Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005 ; 58: 840-846.
11. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 ; 33: 1444-1452.
12. Lublin FD, Reingold SC National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. (1996). Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996 ; 46: 907-911.
13. IMS data, http://www.imshealth.com, and PCRS 2007 Statistical Analysis of Claims and Payments report, http://www.hse.ie (accessed February 2009).
14. Farrell R., Kapoor R., Leary S., et al. Neutralising anti-interferon beta antibodies are associated with reduced side-effects and delayed impact on efficacy of interferon-beta. Mult Scler 2008 ; 14: 212.